Stockreport

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

Compass Therapeutics, Inc.  (CMPX) 
PDF Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025 [Read more]